Join ICON for “Science on Tap” — an evening of discovery, discussion, and holiday cheer! Explore cutting-edge research in precision medicine and bioanalytical laboratory innovation with our expert scientists. If you ar...
Press releases
-
ICON plc to present at the Jefferies London Healthcare Conference
ICON plc today announced that Mr. Barry Balfe, CEO of ICON plc and Mr. Nigel Clerkin, CFO of ICON plc, will present at the Jefferies London Healthcare Conference on Wednesday, November 19, 2025 at 9:00 am GMT.
-
ICON reports third quarter 2025 results
Quarter three revenue was $2,042.8 million representing an increase of 1.3% on quarter two 2025.
-
ICON plc schedules third quarter 2025 earnings conference call
ICON plc today announced that it will release its financial results for the third quarter 2025 after the market closes on Wednesday, October 22, 2025.
-
ICON announces CEO transition
Dr. Steve Cutler has informed the Board of his decision to retire as Chief Executive Officer. Mr. Barry Balfe, ICON’s Chief Operating Officer will succeed Dr. Cutler as Chief Executive Officer effective 1 October 2025.
-
ICON plc to participate at upcoming investor conferences
ICON plc today announced that Mr. Barry Balfe, COO of ICON plc, will present at the Baird 2025 Global Healthcare Conference on Wednesday, September 10, 2025 at 1:25 pm ET and Dr. Steve Cutler, CEO of ICON plc, will participate at the Deutsche Bank 2025 Healthcare Summit on Thursday, September 11, 2025.
-
ICON plc provides update on vaccine study
On August 12, 2025, ICON plc, announced that the large-scale next generation COVID vaccine study that was highlighted on our earnings call on July 24, 2025 as restarted and actively enrolling, has now had a stop work notice issued by BARDA to the sponsor.
-
ICON announces results of annual general meeting
ICON plc today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 22, 2025 were duly passed by shareholders.
-
ICON reports second quarter 2025 results
ICON plc today reported its financial results for the second quarter ended June 30, 2025.
-
ICON’s leadership and performance in phase 1 clinical trials recognised in independent industry benchmarking report
ICON plc has been rated as one of the top-performing contract research organisations (CRO) for phase 1 clinical trials in a benchmarking report from the independent pharmaceutical market research company Industry Standard Research (ISR).
-
ICON and its employees recognised as clinical research industry leaders, and for innovation and progress in sustainability
ICON was also recognised as a Top-Rated Company for Women in the 2025 Ambition Box Employee Choice Awards.
